The $187.5M cash sale of the PRV provides a significant non-dilutive capital boost, strengthening Ascendis's balance sheet and extending its cash runway. Traders should watch for potential use of proceeds (e.g., pipeline investment, debt reduction) in upcoming filings and monitor for any related guidance updates.
ASND drugs
ASND drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 18 $230.83entry
- T+1 · 5mo ago −1.23%α −0.91% · $228.00
- T+5 · 5mo ago +13.32%α +14.99% · $261.58
- T+20 · 4mo ago +12.55%α +12.02% · $259.80
- T+60 · 2mo ago +14.77%α +12.87% · $264.92
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ascendis Pharma completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $187.5 million in cash to an undisclosed buyer. The PRV was awarded by the FDA upon approval of YUVIWEL (navepegritide) in February 2026. This non-dilutive cash infusion provides a significant capital boost for the company's operations.
Key Facts
- Sale of Rare Pediatric Disease Priority Review Voucher (PRV) completed on June 17, 2026
- Proceeds of $187.5 million in cash, before transaction-related expenses
- PRV was awarded by FDA upon approval of YUVIWEL (navepegritide) in February 2026
- Buyer is undisclosed
- Cash infusion is non-dilutive to shareholders
Financial Impact
$187.5 million cash infusion
Risk Factors
- Proceeds are before transaction-related expenses; net amount may be slightly lower
- No specific use of proceeds disclosed yet
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-274306 |
| Document: 0001193125-26-274306-index-headers.html | 0001193125-26-274306 |
| Document: 0001193125-26-274306-index.html | 0001193125-26-274306 |
| Document: 0001193125-26-274306.txt | 0001193125-26-274306 |
Track record
41 reports on ASND
13 of 18 bullish or bearish reports moved the stock their way by T+60. Best: +26.62% at T+20 after the Jun 2, 2026 report. 24 of 26 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $271.96 Now $271.73 −0.08% settles Feb 12
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $275.39 Now $271.73 −1.33% settles Feb 11
- Nov 12, 20264d ago 6-K Bullish 6/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
- Nov 6, 202610d ago 6-K Bullish 6/10 Entry $259.85 Now $271.73 +4.57% settles Feb 5
- Nov 6, 202610d ago Press Release Bullish 6/10 Entry $256.82 Now $271.73 +5.81% settles Feb 4
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $253.45 Now $271.73 +7.21% settles Feb 3
- Nov 2, 202614d ago Institutional Cluster Bullish 4/10 Entry $250.17 Now $271.73 +8.62% settles Feb 1
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $245.85 Now $271.73 +10.53% settles Jan 25
- Oct 16, 20264w ago 6-K Bullish 7/10 Entry $225.25 Now $271.73 +20.63% settles Jan 13
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers